KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Deferred Taxes: 2012-2024

Historic Deferred Taxes for Jazz Pharmaceuticals (JAZZ) over the last 13 years, with Dec 2024 value amounting to -$208.3 million.

  • Jazz Pharmaceuticals' Deferred Taxes fell 321.42% to -$271.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$384.0 million, marking a year-over-year decrease of 58.77%. This contributed to the annual value of -$208.3 million for FY2024, which is 19.94% up from last year.
  • Jazz Pharmaceuticals' Deferred Taxes amounted to -$208.3 million in FY2024, which was up 19.94% from -$260.2 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Deferred Taxes registered a high of $69.2 million during FY2021, and its lowest value of -$292.3 million during FY2022.
  • Its 3-year average for Deferred Taxes is -$253.6 million, with a median of -$260.2 million in 2023.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Deferred Taxes skyrocketed by 150.53% in 2021, and later slumped by 522.34% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Deferred Taxes (Yearly) stood at -$136.9 million in 2020, then skyrocketed by 150.53% to $69.2 million in 2021, then slumped by 522.34% to -$292.3 million in 2022, then climbed by 10.96% to -$260.2 million in 2023, then grew by 19.94% to -$208.3 million in 2024.